TSHA Taysha Corp: Market Capitalization to Book Value Ratio

tayshagtx.com (TSHA) - corporate logo

Taysha Gene Therapies (TSHA) relies on pipeline capital, as stable revenue has not yet been established and developments remain in the testing phase. However, success in treating rare pathologies paves the way for superprofits through monopoly pricing power. This chart illustrates the share price dynamics as 3.44. Taysha Gene Therapies (TSHA) focuses on neurodegenerative disorders, utilizing targeted gene delivery systems and tax preferences associated with orphan drug status.

Taysha Corp (TSHA) Capitalization to Book Value Ratio: for the period 07/04/2022 - 10/31/2026

Taysha Gene Therapies Inc - analytical breakdowns and key metrics (TSHA)

- share price and expert price forecast:
Stock Price Taysha Gene Therapies|TSHA - Analyst Consensus Forecast
- company stock capitalization data:
Market Capitalization Taysha|TSHA - Business Value
- balance sheet net asset value indicators:
Net Assets per Single Share Taysha Gene Therapies|TSHA - Accounting Capitalization|Market Capitalization to Book Value Ratio tayshagtx.com|TSHA - Company Total Assets
- debt and solvency information:
Total Debt to Equity Ratio Taysha Gene Therapies|TSHA - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital Taysha|TSHA - Company Aggregate Debts|Debt to Book Value Taysha|TSHA - Long-Term Debt|Company Short-Term Debt Taysha Gene Therapies|Quick Ratio tayshagtx.com
- earnings and market multiples details:
TSHA - Final Profit
Initial company analysis:Taysha Gene Therapies, TSHA
Finished products of Taysha Gene Therapies Inc

Taysha Gene Therapies (TSHA) dependence on international patent protection and the complexities of cross-border drug registration directly impact the market value of its intangible assets. This indicator compares the market share price with the business's net assets, reflecting a premium for future growth or the risk of undervaluation, which allows for the determination of the strategic development vector through changes in the company's P/BV ratio.

Analysis of competing companies

TEM: Market Capitalization to Book Value Ratio|qiagen.com (QGEN) - Market Capitalization to Book Value Ratio|IONS (Ionis) - Market Capitalization to Book Value Ratio|Capitalization to Book Value Ratio RGEN (Repligen Corp)|Market Value to Book Value Ratio Avidity (RNA)|CRISPR - Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio WGS (GeneDx Holdings Corp.)|Market Capitalization to Book Value Ratio ultragenyx.com RARE|BEAM: Market Cap to Net Assets Ratio|Sarepta Therapeutics - Market Cap to Book Value Multiple|TWST: Market Capitalization to Book Value Ratio|10x (TXG) - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio NTLA|Market-to-Book Ratio stoketherapeutics.com STOK|Market Value to Book Value Ratio BioLife Solutions (BLFS)|Market Capitalization to Book Value Wave Life Sciences Ltd|Market Capitalization to Book Value Ratio MAZE (Maze Tx)|Market Value to Book Value SION|Prime Medicine, Inc. - Market Capitalization to Book Value Ratio|QURE - Market Capitalization to Book Value Ratio|MGTX (MeiraGTx) - Market Cap to Net Assets Ratio|REGENXBIO Inc - Market Value to Book Value|SLDB (Solid Bio) - Market Capitalization to Book Value Ratio|OCGN - Market Value to Equity Ratio|Market Capitalization to Book Value Ratio PACB|BNTC - Market-to-Book Ratio|Market Value to Book Value Ratio Design Therapeutics, Inc. DSGN|RCKT: Capitalization to Book Value Ratio|4D Molecular Therapeutics Inc - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Lexeo Therapeutics|KRRO (korrobio.com) - Market Cap to Net Assets Ratio|editasmedicine.com - Market Value to Book Value|Market Cap to Net Assets Ratio SLN|PRQR (ProQR Therapeutics NV) - Market Cap to Book Value Multiple|Market Capitalization to Book Value Ratio CDXS|SGMO (Sangamo BioSciences) - Market Value to Book Value|Market Capitalization to Book Value Ratio NAUT (Nautilus Bio)|metagenomi.co (MGX) - Market-to-Book Ratio|DTIL - Market Value to Book Value Ratio|Market Value to Book Value GBIO (Generation Bio Co.)|BOLD: Market Capitalization to Book Value Ratio|Exicure (XCUR) - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Imunon Inc|RXi Pharmaceuticals - Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio MBIO|Market Capitalization to Book Value transcodetherapeutics.com|Market Capitalization to Book Value Ratio BNGO (Bionano Genomics)|Applied DNA Corp (APDN) - Market-to-Book Ratio|BLUE - Market Value to Book Value Ratio|Market Capitalization to Book Value ImmunoPrecise Antibodies IPA|OMGA (Omega Therapeutics, Inc.) - Market Cap to Net Assets Ratio|OMIC: Market Cap to Book Value Multiple|Market Value to Book Value Ratio Regulus Therapeutics Inc|Syros Pharmaceuticals, Inc (SYRS) - Market Capitalization to Book Value|Market Capitalization to Book Value Ratio TBIO|TCON (traconpharma.com) - Market Value to Book Value|Market Capitalization to Book Value Ratio UBX (Unity Biotechnology, Inc.)